1
|
Huo L, Liu X, Jaiswal Y, Xu H, Chen R, Lu R, Nong Y, Williams L, Liang Y, Jia Z. Design and Synthesis of Acridine-Triazole and Acridine-Thiadiazole Derivatives and Their Inhibitory Effect against Cancer Cells. Int J Mol Sci 2022; 24:ijms24010064. [PMID: 36613504 PMCID: PMC9820444 DOI: 10.3390/ijms24010064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 12/05/2022] [Accepted: 12/06/2022] [Indexed: 12/24/2022] Open
Abstract
We report herein the design and synthesis of a series of novel acridine-triazole and acridine-thiadiazole derivatives. The newly synthesized compounds and the key intermediates were all evaluated for their antitumor activities against human foreskin fibroblasts (HFF), human gastric cancer cells-803 (MGC-803), hepatocellular carcinoma bel-7404 (BEL-7404), large cell lung cancer cells (NCI-H460), and bladder cancer cells (T24). Most of the compounds exhibited high levels of antitumor activity against MGC-803 and T24 but low toxicity against human normal liver cells (LO2), and their effect was even better than the commercial anticancer drugs, 5-fluorouracil (5-FU) and cis-platinum. Further, pharmacological mechanisms such as topo I, cell cycle, cell apoptosis, and neovascularization were all evaluated. Only a few compounds exhibited potent topo I inhibitory activity at 100 μM. In addition, the most active compounds with an IC50 value of 5.52-8.93 μM were chosen, and they could induce cell apoptosis in the G2 stage of MGC-803 or mainly arrest T24 cells in the S stage. To our delight, most of the compounds exhibited lower zebrafish cytotoxicity but could strongly inhibit the formation of zebrafish sub-intestinal veins, indicating a potential for clinical application.
Collapse
Affiliation(s)
- Lini Huo
- College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530222, China
| | - Xiaochen Liu
- College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530222, China
| | - Yogini Jaiswal
- Center for Excellence in Post-Harvest Technologies, North Carolina Agricultural and Technical State University, The North Carolina Research Campus, 500 Laureate Way, Kannapolis, NC 28081, USA
| | - Hao Xu
- College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530222, China
| | - Rui Chen
- College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530222, China
- Correspondence: (R.C.); (R.L.)
| | - Rumei Lu
- College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530222, China
- Correspondence: (R.C.); (R.L.)
| | - Yaqin Nong
- College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530222, China
| | - Leonard Williams
- Center for Excellence in Post-Harvest Technologies, North Carolina Agricultural and Technical State University, The North Carolina Research Campus, 500 Laureate Way, Kannapolis, NC 28081, USA
| | - Yan Liang
- College of Pharmacy, Guangxi Medical University, Nanning 530021, China
| | - Zhiruo Jia
- College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530222, China
| |
Collapse
|
2
|
Synthesis and Biological Evaluation of Some 1,8-Naphthalimide-Acridinyl Hybrids. J CHEM-NY 2020. [DOI: 10.1155/2020/7989852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
In the present study, the synthesis of three 1,8-naphthalimide-acridinyl hybrids (2a, 2b, and 5b) using N-amido-1,8-naphthalimides (1 and 4) and acridinyl isothiocyanates is reported. The newly synthesized hybrids were evaluated for their anticancer activity in six human cancer cell lines (HL-60, MT-4, HepG2, HeLa, SK-OV-3, and MCF-7). Their inhibition activity against DNA-topoisomerase I (Topo I) and Electrophorus electricus acetylcholinesterase (AChE) was also studied. The results indicate that 2b displayed good cytotoxicity for MT-4, HepG2, HeLa, and SK-OV-3 with the IC50 values of 14.66 ± 0.31, 27.32 ± 2.67, 17.51 ± 0.34, and 32.26 ± 1.74 μM, respectively. All compounds, especially 2b, exhibited obvious bands corresponding to DNA fragments at 0.5 mM concentration, further confirming the pharmacological mechanism related to the Topo I inhibitory activities. In addition, compound 2a exhibited higher inhibition activity against AChE than 2b and 5b, with IC50 values of 0.32 ± 0.04 mM, and the acridinyl ring may contribute to the activity of 2a.
Collapse
|
3
|
Chen R, Huang J, Jaiswal Y, Wei J, Huo L, Xia X, Zhong J, Williams L, Huang M, Liang Y. Molecular Design, Synthesis and Docking Study of Alkyl and Benzyl Derivatives of Robustic Acid as Topoisomerase I Inhibitors. Chem Biodivers 2020; 17:e1900556. [PMID: 31943759 DOI: 10.1002/cbdv.201900556] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2019] [Accepted: 01/13/2020] [Indexed: 12/15/2022]
Abstract
Robustic acid is reported to be a bioactive compound, isolated from the medicinal plant Dalbergia benthamii Prain. Ten alkyl and benzyl derivatives (2a-2j) of robustic acid were designed and synthesized based on molecular docking approaches. The biological activities of most of the synthesized compounds (such as 2g, 2h, and 2i) were closely consistent with the docking results. In particular, 4-O-phenylpropyl substituted compound 2g displayed potent topoisomerase I inhibitory activity as well as cytotoxicity against SMMC-7721, HepG2, and HeLa cell lines. Further biological testing suggests that compound 2g acted mainly by an arrest of the tumor cells in G1 phase of the cell cycle and suppressed cell proliferation by inducing apoptosis. The findings of this study are encouraging with respect to potential utilization of these compounds as new topoisomerase I inhibitors.
Collapse
Affiliation(s)
- Rui Chen
- Institute of Pharmacy, Guangxi University of Chinese Medicine, Nanning, 530222, P. R. China.,Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, Nanning, 530222, P. R. China
| | - Jiayong Huang
- Institute of Pharmacy, Guangxi University of Chinese Medicine, Nanning, 530222, P. R. China
| | - Yogini Jaiswal
- Center for Excellence in Post-Harvest Technologies, North Carolina A&T State University, The North Carolina Research Campus, 500 Laureate Way, Kannapolis, NC-28081, USA
| | - Jianhua Wei
- Institute of Pharmacy, Guangxi University of Chinese Medicine, Nanning, 530222, P. R. China
| | - Lini Huo
- Institute of Pharmacy, Guangxi University of Chinese Medicine, Nanning, 530222, P. R. China
| | - Xing Xia
- Institute of Pharmacy, Guangxi University of Chinese Medicine, Nanning, 530222, P. R. China
| | - Jing Zhong
- Institute of Pharmacy, Guangxi University of Chinese Medicine, Nanning, 530222, P. R. China
| | - Leonard Williams
- Center for Excellence in Post-Harvest Technologies, North Carolina A&T State University, The North Carolina Research Campus, 500 Laureate Way, Kannapolis, NC-28081, USA
| | - Maochun Huang
- Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, Nanning, 530222, P. R. China
| | - Yan Liang
- Guangxi Medical University, Nanning, 530021, P. R. China
| |
Collapse
|